We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Ono Pharmaceutical Co. (OPHLF): Can Its 9.2% Jump Turn into More Strength?
Read MoreHide Full Article
Ono Pharmaceutical Co. (OPHLF - Free Report) shares rallied 9.2% in the last trading session to close at $14.61. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.9% loss over the past four weeks.
Ono Pharmaceutical's recent share price appreciation reflects improving investor confidence in the company's expanding oncology and specialty medicine portfolio, underpinned by consistent pipeline execution. Investor sentiment has been supported by multiple regulatory milestones for Opdivo (nivolumab), the company's largest revenue-generating product, continued clinical advancement of Velexbru (tirabrutinib), encouraging mid-stage data for pipeline candidates ONO-4578 and ONO-2808, and the regulatory filing of Qinlock in Japan. In addition, the growing contribution from newer products such as Romvimza, along with the expansion of the company's rare disease and oncology portfolio, is expected to diversify revenue streams beyond Opdivo, enhancing Ono's long-term growth prospects and reinforcing positive investor sentiment.
This company is expected to post quarterly earnings of $0.25 per share in its upcoming report, which represents a year-over-year change of -3.9%. Revenues are expected to be $693.95 million, down 21.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Ono Pharmaceutical Co., the consensus EPS estimate for the quarter has been revised 4% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on OPHLF going forward to see if this recent jump can turn into more strength down the road.
Ono Pharmaceutical Co. is part of the Zacks Medical - Drugs industry. Korro Bio, Inc. (KRRO - Free Report) , another stock in the same industry, closed the last trading session 7.7% lower at $10.64. KRRO has returned -5.3% in the past month.
Korro Bio, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$1.54. Compared to the company's year-ago EPS, this represents a change of +43.8%. Korro Bio, Inc. currently boasts a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Strength Seen in Ono Pharmaceutical Co. (OPHLF): Can Its 9.2% Jump Turn into More Strength?
Ono Pharmaceutical Co. (OPHLF - Free Report) shares rallied 9.2% in the last trading session to close at $14.61. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.9% loss over the past four weeks.
Ono Pharmaceutical's recent share price appreciation reflects improving investor confidence in the company's expanding oncology and specialty medicine portfolio, underpinned by consistent pipeline execution. Investor sentiment has been supported by multiple regulatory milestones for Opdivo (nivolumab), the company's largest revenue-generating product, continued clinical advancement of Velexbru (tirabrutinib), encouraging mid-stage data for pipeline candidates ONO-4578 and ONO-2808, and the regulatory filing of Qinlock in Japan. In addition, the growing contribution from newer products such as Romvimza, along with the expansion of the company's rare disease and oncology portfolio, is expected to diversify revenue streams beyond Opdivo, enhancing Ono's long-term growth prospects and reinforcing positive investor sentiment.
This company is expected to post quarterly earnings of $0.25 per share in its upcoming report, which represents a year-over-year change of -3.9%. Revenues are expected to be $693.95 million, down 21.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Ono Pharmaceutical Co., the consensus EPS estimate for the quarter has been revised 4% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on OPHLF going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Ono Pharmaceutical Co. is part of the Zacks Medical - Drugs industry. Korro Bio, Inc. (KRRO - Free Report) , another stock in the same industry, closed the last trading session 7.7% lower at $10.64. KRRO has returned -5.3% in the past month.
Korro Bio, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$1.54. Compared to the company's year-ago EPS, this represents a change of +43.8%. Korro Bio, Inc. currently boasts a Zacks Rank of #3 (Hold).